Therapy News and Research

RSS

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Vanishing bile duct syndrome refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Kinetic Concepts enters injunction against Smith & Nephew to prohibit infringement of two patents

Kinetic Concepts, Inc. today announced that the High Court of Justice Chancery Division, Patents Court in the United Kingdom has entered an injunction against Smith & Nephew plc prohibiting infringement of two KCI patents relating to negative pressure wound therapy ("NPWT"). The Court stayed the injunction pending appeal, which is expected in October of this year.

31 Jul 2010

Oral contraceptives, HRT may protect women against formation, rupture of brain aneurysms: Study

Results from a new study suggest that oral contraceptives and hormone replacement therapy may yield additional benefit of protecting against the formation and rupture of brain aneurysms in women. The findings from this first-of-its-kind study by a neurointerventional expert from Rush University Medical Center were presented at the Society of Neurointerventional Surgery 7th annual meeting.

31 Jul 2010

Angiotech reports $61.9 million total revenue for second-quarter 2010

Angiotech Pharmaceuticals, Inc. today announced its financial results for the second quarter ended June 30, 2010.

31 Jul 2010

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Competitive Technologies, Inc. announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT's Calmare® Pain Therapy medical device.

31 Jul 2010

HealthSouth plans new rehabilitation hospital in northwest Houston

HealthSouth Corporation today announced plans to begin construction of a new 40-bed inpatient rehabilitation hospital in the Cypress area of northwest Houston in the fourth quarter. In connection with such plans, HealthSouth has signed a contract to purchase a 6-acre tract of land from an affiliate of Caldwell Companies, based in Houston. The land is located on the northeast corner of Highway 290 and FM 1960 in Houston.

31 Jul 2010

Water Street Healthcare Partners acquires Medical Specialties Distributors

Water Street Healthcare Partners, a leading private equity firm focused exclusively on health care, announced today that it has acquired Medical Specialties Distributors, LLC (MSD). Headquartered in Stoughton, Massachusetts, MSD is the nation's leading provider of infusion products, supplies, biomedical services and technology solutions to the growing home infusion therapy market. The acquisition expands Water Street's current group of health care companies to 12.

From Baxter International Inc. 31 Jul 2010

Researchers suggest soybean isoflavones enhance bone health

Scientists already know much about the more than 200 bones that make up your body. But mysteries remain regarding the exact role that many natural compounds in foods might play in strengthening our skeletons. Those compounds include estrogen-like substances known as soybean isoflavones.

31 Jul 2010

Scientists identify enzyme to prevent beta-amyloids formation in Alzheimer patients

The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.

31 Jul 2010

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

Study shows estrogen stabilization may protect women from brain aneurysms risk

Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have significant implications for women at risk of brain aneurysms as data shows that oral contraceptives (OC) and hormone replacement therapy (HRT) may yield the additional benefit of protecting against the formation and/or rupture of brain aneurysms – balloon-like sacks that form in a weakened artery wall and, upon bursting, can cause severe disability or death.

31 Jul 2010

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Volcano second-quarter revenues increase 36% to record $73.5 million

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that revenues in the second quarter of 2010 increased 36 percent versus revenues in the second quarter of 2009.

30 Jul 2010

Partners in ENIAC project announce details of multinational/multidisciplinary program

The partners in a new publicly-funded European research project today announced details of the multinational/multidisciplinary program: 'CSI: Central Nervous System Imaging.' This three-year ENIAC project aims to achieve substantial advances in state-of-the-art medical 3D-imaging platforms by focusing on the diagnosis and therapy of serious diseases of the central nervous system and brain.

30 Jul 2010

Anadys Pharmaceuticals reports SVR12 data for ANA598

Anadys Pharmaceuticals, Inc. today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.

30 Jul 2010

Families with male breast cancer perceive as being at higher risk: Study

People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family history of female breast cancer, according to a study led by researchers at the University of Louisville's James Graham Brown Cancer Center.

30 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

30 Jul 2010

Therapy News and Research

Cell-of-origin for prostate cancer identified

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Kinetic Concepts enters injunction against Smith & Nephew to prohibit infringement of two patents

Oral contraceptives, HRT may protect women against formation, rupture of brain aneurysms: Study

Angiotech reports $61.9 million total revenue for second-quarter 2010

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

HealthSouth plans new rehabilitation hospital in northwest Houston

Water Street Healthcare Partners acquires Medical Specialties Distributors

Researchers suggest soybean isoflavones enhance bone health

Scientists identify enzyme to prevent beta-amyloids formation in Alzheimer patients

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Study shows estrogen stabilization may protect women from brain aneurysms risk

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Volcano second-quarter revenues increase 36% to record $73.5 million

Partners in ENIAC project announce details of multinational/multidisciplinary program

Anadys Pharmaceuticals reports SVR12 data for ANA598

Families with male breast cancer perceive as being at higher risk: Study

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News